Cost Effectiveness of Introducing Pneumococcus Vaccine in a Sri Lankan Community: Epidemiology and Economic Analysis - Methodology

Presenter: Sanjeewa Kularatna, University of Peradeniya

Abstract

Pneumonia, meningitis, and sepsis are a major threat to the health of the children worldwide. Especially in the south East Asia pneumococcus associated invasive disease is the number one vaccine preventable cause of death in children under 5.

Introduction of pneumococcus vaccine is supposed to reduce the disease burden, mortality and cost of treatment.

More over like any other developing country, in Sri Lanka too, resources are scarce. Therefore decisions such as introduction of a new intervention need to be evidence based.

This study consists of three components. First component estimate the disease burden of(Invasive Pneumococcal Disease( IPD). Second component is economic burden study which evaluates the cost for treatment of the disease. Thirdly the incremental costs associated with the introduction of new vaccine into the system are evaluated.

Expected results are the incidence of IPD, direct medical costs, indirect medical costs, indirect costs and incremental costs for immunization programme.

Then a simulation model (Markov model) will be built to analyses the cost effectiveness of the new intervention. Results will be given in public health sector, household and societal perspectives. Cost effectiveness will be determined for a range of incidence figures to give results for best and worst case scenarios.